Singapore Healthcare - Decoupling Opportunities | POSITIVE
Maintain overweight, our top picks are Raffles Medical, Q&M and ISEC, catalysts from further expansion and more M&As.
We downgrade Cordlife to HOLD, as it has rallied significantly.
The healthcare stocks’ earnings have been resilient, but stock performances correlate with the broad market in uncertain times, diverging away from their fundamentals.
We think that current weakness caused by weaker sentiment and stake reductions by institutional investors could present buying opportunities.
Source: Kim Eng
|
|
Healthcare 02 (May 15 - Dec 25)
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Thu Jan 21, 2016 9:52 am
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Tue Feb 23, 2016 7:28 am
The Next Boom to Go Bust
By Adam O’Dell
Last October, I voiced my growing concern over bubble-like excesses in the health care industry.
I showed how the most speculative and volatile subsets of the health care industry – biotech and pharmaceuticals – had enjoyed a massive boom since the March 2009 bottom.
By last July, pharmaceutical stocks (XPH) were up 455%, and biotech stocks (XBI) were up 520%!
These insanely high prices, to me, looked eerily similar to the bubble-like prices we saw in mining stocks in early 2011, and in oil and gas stocks in early 2014.
Hence, my suspicion that our beloved health care industry might just be “the next boom to go bust.”
And I warned you that two health care ETFs – the SPDR S&P Biotech ETF (NYSE: XBI) and the SPDR S&P Pharmaceuticals ETF (NYSE: XPH) – could lose between 45% and 70% in as little as 12 to 18 months.
It was a bold warning, I realize.
But so far, I’ve been right. Pharmaceutical and biotech stocks have taken a beating in the last four months, losing 15% and 26%, respectively!
That should make you take notice!
Of course, back in October, not everyone agreed with my skepticism of the health care industry.
In fact, one Boom & Bust subscriber wrote to say it was one of the “lamest explanations” he’s ever heard.
Paid-up subscriber Eric B. said:
The enablement of health care cost growth has been occurring since just about the inception of Medicare. Cost containment has been a recurring political issue during that entire time frame. So what makes you think that now is the time we have the political will to ignore the special interest groups in a trillion + dollar industry?
You now have a very significant (and growing) voting bloc (the baby boomers) who are dependent upon Medicare for their health care insurance. If their health care choices begin to diminish, they will become politically militant and threaten the withdrawal of support of their legislators. So again, what makes you think that now is the golden moment for health care cost containment?
Hey, I hear ya Eric!
As I said last fall, the health care industry has in recent years been one of the most robust and promising sectors of the U.S. economy. Fundamentally, the baby boomer generation has been, and will continue to be, a driving force of demand for health care services, equipment and pharmaceuticals.
But that doesn’t mean baby boomers will let the industry get away with murder!
Earlier this month, executives from Valeant Pharmaceuticals International (NYSE: VRX), alongside biotech’s notorious bad boy, Martin Shkreli, had a lot of explaining to do when they were subpoenaed to appear before Congress.
The topic of the day: price hikes of 212%... 525%... and 5,000%... on previously inexpensive, life-saving drugs…
Now, I realize it’s easy to shrug off the 5,000% price hike that the most-hated man in health care (Shkreli) enacted. “He’s an outlier… just one bad apple,” some people claim.
But Valeant Pharmaceuticals isn’t some fly-by-night scam artist, as Shkreli might prove to be. Valeant is a $32 billion company with 33 years of operating history.
What’s more, it’s highly doubtful that abuses of pricing power are limited to just these two.
According to a 2014 report in FiercePharma, there are at least 10 examples of insane drug price hikes… by major drug companies… prior to the 5,000% increase that shoved pharma’s dubious practices into the mainstream media circuit.
We’re talking about price hikes between 159% for Pfizer’s (NYSE: PFE) Viagra, to 841% for a narcolepsy drug made by Jazz Pharmaceuticals (NYSE: JAZZ).
Other documents obtained by Congress led Representative Elijah Cummings to conclude: “these tactics are not limited to a few ‘bad apples,’ but are prominent throughout the industry.”
Basically, in the words of Forbes columnist Arlene Weintraub: “[Shkreli’s former company] and Valeant are merely the poster children for what Congress now realizes is a much bigger trend in the pharma industry to raise prices to whatever the market will bear.”
I anticipate more trouble ahead for the industry’s lofty stock prices, especially now that a bright light is getting shone on the shady practices of Big Pharma and Biotech.
So now, the fight begins.
Drug-makers will claim they need to raise prices to fund future research and develop… oh, and to fulfill their duty to shareholders.
And opponents will argue that the price gouging is excessive, unsustainable and perhaps even unethical… since, at the end of the day, we’re talking about peoples’ health here!
While that fight unfolds – on a public stage, nonetheless – I think it’s best to maintain a healthy dose of skepticism when it comes to pricing practices of Big Pharma and Biotech.
And steer clear of their stocks!
Source: Dent Research
By Adam O’Dell
Last October, I voiced my growing concern over bubble-like excesses in the health care industry.
I showed how the most speculative and volatile subsets of the health care industry – biotech and pharmaceuticals – had enjoyed a massive boom since the March 2009 bottom.
By last July, pharmaceutical stocks (XPH) were up 455%, and biotech stocks (XBI) were up 520%!
These insanely high prices, to me, looked eerily similar to the bubble-like prices we saw in mining stocks in early 2011, and in oil and gas stocks in early 2014.
Hence, my suspicion that our beloved health care industry might just be “the next boom to go bust.”
And I warned you that two health care ETFs – the SPDR S&P Biotech ETF (NYSE: XBI) and the SPDR S&P Pharmaceuticals ETF (NYSE: XPH) – could lose between 45% and 70% in as little as 12 to 18 months.
It was a bold warning, I realize.
But so far, I’ve been right. Pharmaceutical and biotech stocks have taken a beating in the last four months, losing 15% and 26%, respectively!
That should make you take notice!
Of course, back in October, not everyone agreed with my skepticism of the health care industry.
In fact, one Boom & Bust subscriber wrote to say it was one of the “lamest explanations” he’s ever heard.
Paid-up subscriber Eric B. said:
The enablement of health care cost growth has been occurring since just about the inception of Medicare. Cost containment has been a recurring political issue during that entire time frame. So what makes you think that now is the time we have the political will to ignore the special interest groups in a trillion + dollar industry?
You now have a very significant (and growing) voting bloc (the baby boomers) who are dependent upon Medicare for their health care insurance. If their health care choices begin to diminish, they will become politically militant and threaten the withdrawal of support of their legislators. So again, what makes you think that now is the golden moment for health care cost containment?
Hey, I hear ya Eric!
As I said last fall, the health care industry has in recent years been one of the most robust and promising sectors of the U.S. economy. Fundamentally, the baby boomer generation has been, and will continue to be, a driving force of demand for health care services, equipment and pharmaceuticals.
But that doesn’t mean baby boomers will let the industry get away with murder!
Earlier this month, executives from Valeant Pharmaceuticals International (NYSE: VRX), alongside biotech’s notorious bad boy, Martin Shkreli, had a lot of explaining to do when they were subpoenaed to appear before Congress.
The topic of the day: price hikes of 212%... 525%... and 5,000%... on previously inexpensive, life-saving drugs…
Now, I realize it’s easy to shrug off the 5,000% price hike that the most-hated man in health care (Shkreli) enacted. “He’s an outlier… just one bad apple,” some people claim.
But Valeant Pharmaceuticals isn’t some fly-by-night scam artist, as Shkreli might prove to be. Valeant is a $32 billion company with 33 years of operating history.
What’s more, it’s highly doubtful that abuses of pricing power are limited to just these two.
According to a 2014 report in FiercePharma, there are at least 10 examples of insane drug price hikes… by major drug companies… prior to the 5,000% increase that shoved pharma’s dubious practices into the mainstream media circuit.
We’re talking about price hikes between 159% for Pfizer’s (NYSE: PFE) Viagra, to 841% for a narcolepsy drug made by Jazz Pharmaceuticals (NYSE: JAZZ).
Other documents obtained by Congress led Representative Elijah Cummings to conclude: “these tactics are not limited to a few ‘bad apples,’ but are prominent throughout the industry.”
Basically, in the words of Forbes columnist Arlene Weintraub: “[Shkreli’s former company] and Valeant are merely the poster children for what Congress now realizes is a much bigger trend in the pharma industry to raise prices to whatever the market will bear.”
I anticipate more trouble ahead for the industry’s lofty stock prices, especially now that a bright light is getting shone on the shady practices of Big Pharma and Biotech.
So now, the fight begins.
Drug-makers will claim they need to raise prices to fund future research and develop… oh, and to fulfill their duty to shareholders.
And opponents will argue that the price gouging is excessive, unsustainable and perhaps even unethical… since, at the end of the day, we’re talking about peoples’ health here!
While that fight unfolds – on a public stage, nonetheless – I think it’s best to maintain a healthy dose of skepticism when it comes to pricing practices of Big Pharma and Biotech.
And steer clear of their stocks!
Source: Dent Research
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Tue Mar 08, 2016 9:29 am
Singapore: Healthcare Sector: Mixed 4Q performance across sub-sectors
As a recap, under our coverage, Raffles Medical Group’s 4Q earnings were within expectations and the group continues to grow as planned.
No surprises came from Biosensors International’s results as well.
For the other companies, glove players continued to perform well, while IHH Healthcare Berhad and Q&M Dental recorded profit erosion in 4Q due to expansion-driven costs.
With plans for a two decade overhaul for the Singapore General Hospital and the implementation of new models of care, long term prospects for the local healthcare sector remains clear.
Following the outperformance of the FTSE ST Health Care Index (FSTHC) in 2015, the pace however has slowed for FSTHC, gaining only 1.4% vs. the STI’s decline of 0.4% YTD.
The FSTHC forward PER currently remains above its 2-year historical average, still unattractive on a broad-based level.
Moreover, with the mixed outlook across sub-sectors, we maintain a NEUTRAL rating on the overall healthcare sector. Raffles Medical Group [BUY, S$4.72] remains our pick.
Source: OCBC
As a recap, under our coverage, Raffles Medical Group’s 4Q earnings were within expectations and the group continues to grow as planned.
No surprises came from Biosensors International’s results as well.
For the other companies, glove players continued to perform well, while IHH Healthcare Berhad and Q&M Dental recorded profit erosion in 4Q due to expansion-driven costs.
With plans for a two decade overhaul for the Singapore General Hospital and the implementation of new models of care, long term prospects for the local healthcare sector remains clear.
Following the outperformance of the FTSE ST Health Care Index (FSTHC) in 2015, the pace however has slowed for FSTHC, gaining only 1.4% vs. the STI’s decline of 0.4% YTD.
The FSTHC forward PER currently remains above its 2-year historical average, still unattractive on a broad-based level.
Moreover, with the mixed outlook across sub-sectors, we maintain a NEUTRAL rating on the overall healthcare sector. Raffles Medical Group [BUY, S$4.72] remains our pick.
Source: OCBC
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Tue Mar 08, 2016 2:37 pm
China: Remaining constructive on the sector due to valuation/growth outlook
Hospital data indicates 3.2% YoY growth in 4Q15 vs. 5.8% YTD 3Q15, exhibiting further growth deceleration.
Industry executives attribute this to volume growth weakness rather than pricing pressure.
For 4Q15, we expect 3SBio, Sino Biopharm, Hengrui, CSPC to deliver robust results, in line with street expectations.
We reiterate our top picks as CBPO, 3SBio and Hengrui.
We initiate coverage of Fosun-A and Shanghai Pharma-A with Holds.
Source: DB
Hospital data indicates 3.2% YoY growth in 4Q15 vs. 5.8% YTD 3Q15, exhibiting further growth deceleration.
Industry executives attribute this to volume growth weakness rather than pricing pressure.
For 4Q15, we expect 3SBio, Sino Biopharm, Hengrui, CSPC to deliver robust results, in line with street expectations.
We reiterate our top picks as CBPO, 3SBio and Hengrui.
We initiate coverage of Fosun-A and Shanghai Pharma-A with Holds.
Source: DB
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Sun Mar 13, 2016 8:02 am
Breakthrough innovations master deadly disease
This is one of the most exciting times to be alive. Not just because of the incredible technological advances we’ll see in the coming years… but because we could be on the cusp of completely eliminating several killer diseases altogether.
The first step on the road to a massive increase in human longevity is to have healthier bodies and healthier minds.
I aspire to living a healthier life and I’m sure you do too but the reality is that we are too often the victim of our environment and genetics. There is very little we can do to avoid the twin terrors of cancer and Alzheimer’s and everyone knows someone who has had to deal with these afflictions. The first cripples the body while the other assails the mind.
Mental health (11%), circulation problems (7.2%) and cancer treatment (5.4%) represent the three biggest spending centres for the NHS and this has been the case since 2004/05. With the number of retirees set to increase substantially over the next couple of decades the cost of caring for all these people if going to skyrocket. Finding a solution to this problem is in everyone’s interests and the potential exists for it to be solved outright.
An increasing number of scientists are now tackling the issue of death as a disease rather than the ultimate condition. They are attempting to solve the puzzle of how to not only extend life but enhance the quality of life we enjoy.
The Imperial Cancer Research Fund was founded 114 years ago, which gives us an idea of just how long investigation into the topic has been ongoing for. After all that time the pace of innovation is finally bearing fruit. Survival rates have improved rapidly for many cancers. Cervical cancer now has a vaccine.
That’s just one attack vector for the solution to how we are going to conquer the diseases that plague humanity. In September scientists in Denmark and Canada, working on how to treat pregnant women who have contracted malaria, realised that the carbohydrate malaria attaches to the placental wall is also present in cancer. By arming that protein with a toxin they were then able to use the portal to kill cancer.
But that’s just the start of a much wider trend. This isn’t just a cancer story. It’s the story of humanity finally overcoming many of the world’s most deadly diseases.
Take Alzheimer’s, for instance. It was a stranded disease for a long time because there was a perception it was natural for old people to become befuddled as they aged. Alzheimer’s was identified as a disease in 1908 but the Alzheimer’s Association was only founded in 1980.
From my own family, my grandmother, who was one of the most intelligent people I have ever met, realised she was losing her faculties at the age of 83 and stopped taking medication for her heart condition. She died at 84 more out of choice than any other factor. Her sister and brother both lived into their late ‘90s and spent the last 15 years of their lives developing progressively more acute symptoms of what is a terrible degenerative disease.
With people living longer the cost of treating the disease is ballooning; $200 billion last year in the USA. Perhaps the greatest motivator for investment is that the legions of baby boomers now retiring vote and have a vested interest in finding a cure. Progress in treating this disease is leaping forward and clinical trials are already taking place.
We all spend our lives working toward a retirement we wish to enjoy but what good is that if we spend the final twenty years of our lives with no memory of our loved ones and confined to bed for years; existing as vegetables.
Curing Alzheimer’s is going to be huge business because this is a problem we can solve. It’s going to have a profound effect on demographics and the way we think about our lives and how productive we can be.
What’s making this all possible?
One breakthrough I’m particularly excited about is gene editing.
This year a number of companies pioneering CRISPR gene editing technology will IPO. Google, Bill Gates and big pharma has been pouring money into this sector.
Why you might ask?
Well, about 10 years ago scientists discovered that bacteria can chop invading viruses by attacking their DNA sequences. They figured out how to replicate that and now gene editing is on the cusp of a major growth spurt. This means that the potential now exists to splice into a DNA sequence cut out the offending code and replace it.
The possible permutations are almost limitless so big computers will be required to comprehend the data, but access to this information will be widely available so the potential for innovation at a low cost is incredible. Cures for Cancer, Alzheimer’s, obesity and heart disease all lay within the realm of the possible with this emerging technology.
Don’t even get me started about diabetes but let me make one more point. There have been a lot stories about the prices pharmaceutical companies have been charging for their products. There are some logical arguments when applied to old drugs with new owners but how can one possibly put a price on life and particularly quality of life?
That alone will ensure the companies delivering solutions to humanity’s most intractable challenges will be very well compensated.
Source: Exponential Investor
This is one of the most exciting times to be alive. Not just because of the incredible technological advances we’ll see in the coming years… but because we could be on the cusp of completely eliminating several killer diseases altogether.
The first step on the road to a massive increase in human longevity is to have healthier bodies and healthier minds.
I aspire to living a healthier life and I’m sure you do too but the reality is that we are too often the victim of our environment and genetics. There is very little we can do to avoid the twin terrors of cancer and Alzheimer’s and everyone knows someone who has had to deal with these afflictions. The first cripples the body while the other assails the mind.
Mental health (11%), circulation problems (7.2%) and cancer treatment (5.4%) represent the three biggest spending centres for the NHS and this has been the case since 2004/05. With the number of retirees set to increase substantially over the next couple of decades the cost of caring for all these people if going to skyrocket. Finding a solution to this problem is in everyone’s interests and the potential exists for it to be solved outright.
An increasing number of scientists are now tackling the issue of death as a disease rather than the ultimate condition. They are attempting to solve the puzzle of how to not only extend life but enhance the quality of life we enjoy.
The Imperial Cancer Research Fund was founded 114 years ago, which gives us an idea of just how long investigation into the topic has been ongoing for. After all that time the pace of innovation is finally bearing fruit. Survival rates have improved rapidly for many cancers. Cervical cancer now has a vaccine.
That’s just one attack vector for the solution to how we are going to conquer the diseases that plague humanity. In September scientists in Denmark and Canada, working on how to treat pregnant women who have contracted malaria, realised that the carbohydrate malaria attaches to the placental wall is also present in cancer. By arming that protein with a toxin they were then able to use the portal to kill cancer.
But that’s just the start of a much wider trend. This isn’t just a cancer story. It’s the story of humanity finally overcoming many of the world’s most deadly diseases.
Take Alzheimer’s, for instance. It was a stranded disease for a long time because there was a perception it was natural for old people to become befuddled as they aged. Alzheimer’s was identified as a disease in 1908 but the Alzheimer’s Association was only founded in 1980.
From my own family, my grandmother, who was one of the most intelligent people I have ever met, realised she was losing her faculties at the age of 83 and stopped taking medication for her heart condition. She died at 84 more out of choice than any other factor. Her sister and brother both lived into their late ‘90s and spent the last 15 years of their lives developing progressively more acute symptoms of what is a terrible degenerative disease.
With people living longer the cost of treating the disease is ballooning; $200 billion last year in the USA. Perhaps the greatest motivator for investment is that the legions of baby boomers now retiring vote and have a vested interest in finding a cure. Progress in treating this disease is leaping forward and clinical trials are already taking place.
We all spend our lives working toward a retirement we wish to enjoy but what good is that if we spend the final twenty years of our lives with no memory of our loved ones and confined to bed for years; existing as vegetables.
Curing Alzheimer’s is going to be huge business because this is a problem we can solve. It’s going to have a profound effect on demographics and the way we think about our lives and how productive we can be.
What’s making this all possible?
One breakthrough I’m particularly excited about is gene editing.
This year a number of companies pioneering CRISPR gene editing technology will IPO. Google, Bill Gates and big pharma has been pouring money into this sector.
Why you might ask?
Well, about 10 years ago scientists discovered that bacteria can chop invading viruses by attacking their DNA sequences. They figured out how to replicate that and now gene editing is on the cusp of a major growth spurt. This means that the potential now exists to splice into a DNA sequence cut out the offending code and replace it.
The possible permutations are almost limitless so big computers will be required to comprehend the data, but access to this information will be widely available so the potential for innovation at a low cost is incredible. Cures for Cancer, Alzheimer’s, obesity and heart disease all lay within the realm of the possible with this emerging technology.
Don’t even get me started about diabetes but let me make one more point. There have been a lot stories about the prices pharmaceutical companies have been charging for their products. There are some logical arguments when applied to old drugs with new owners but how can one possibly put a price on life and particularly quality of life?
That alone will ensure the companies delivering solutions to humanity’s most intractable challenges will be very well compensated.
Source: Exponential Investor
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Thu Mar 17, 2016 11:58 am
7 Big Pharma & Biotech Stocks to Sell or Short
These stocks just don't have chemistry with the markets right now
By Anthony Mirhaydari
Source: Investor Place
http://investorplace.com/2016/03/biotec ... uoqqvl96M8
These stocks just don't have chemistry with the markets right now
By Anthony Mirhaydari
Source: Investor Place
http://investorplace.com/2016/03/biotec ... uoqqvl96M8
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Thu Mar 31, 2016 7:38 pm
BIOTECH BLUES CONTINUE
Today's chart shows that one of the market's greatest "boom and bust" sectors is in "bust" mode...
As regular readers know, folks love the idea of investing in the next blockbuster drug or "miracle pill." This draws in speculative money flows. As we often say... get in early on the booms, avoid the busts, and you can make great money in biotech.
But right now, biotech is struggling. We can see this by looking at the iShares Nasdaq Biotechnology Fund (IBB). This fund's largest holdings include some of the biggest names in the sector, such as Celgene (CELG), Biogen (BIIB), Amgen (AMGN), and Gilead Sciences (GILD).
As you can see below, biotech was in boom mode from April 2014 through June 2015. But the trend has reversed course, and IBB shares have sunk more than 30% over the past eight months. For now, it's a bear market in biotech...
Source: Daily Wealth
Today's chart shows that one of the market's greatest "boom and bust" sectors is in "bust" mode...
As regular readers know, folks love the idea of investing in the next blockbuster drug or "miracle pill." This draws in speculative money flows. As we often say... get in early on the booms, avoid the busts, and you can make great money in biotech.
But right now, biotech is struggling. We can see this by looking at the iShares Nasdaq Biotechnology Fund (IBB). This fund's largest holdings include some of the biggest names in the sector, such as Celgene (CELG), Biogen (BIIB), Amgen (AMGN), and Gilead Sciences (GILD).
As you can see below, biotech was in boom mode from April 2014 through June 2015. But the trend has reversed course, and IBB shares have sunk more than 30% over the past eight months. For now, it's a bear market in biotech...
Source: Daily Wealth
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Tue Apr 05, 2016 9:45 am
3 Biotech Stocks on the Verge of an Overdue Run (AMGN, GILD, REGN)
Underloved for too long, money is now rotating into biotech stocks once more
By Tyler Craig
Source: Tyler's Trading
http://investorplace.com/2016/04/biotec ... wMOO6R96M8
Underloved for too long, money is now rotating into biotech stocks once more
By Tyler Craig
Source: Tyler's Trading
http://investorplace.com/2016/04/biotec ... wMOO6R96M8
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Tue Apr 05, 2016 8:04 pm
China's Middle Class Will Fork Over $1 Trillion for This Must-Have Service by 2020
Here's the best direct play on this impending boom...
By MICHAEL A. ROBINSON
Source: Money Morning
http://moneymorning.com/2016/04/05/chin ... e-by-2020/
Here's the best direct play on this impending boom...
By MICHAEL A. ROBINSON
In 2015, more than 56% of China's citizens live in its cities.
From 2010 through 2025, China's Ministry of Housing and Urban-Rural Development estimates 300 million Chinese will move to the cities, creating at least CN¥1 trillion ($154 billion) in annual infrastructure investment opportunities alone.
According to Caixin Online, in 2009, China's online healthcare delivery business was worth about $31 million.
But by 2015, that figure had jumped more than 674% to $2.4 billion.
In a very telling case, online retailer Tencent Holdings Ltd. (OTCMKTS ADR: TCEHY) is investing $100 million in its new startup, We Doctor Group (aka Medical Service Guahao). Tencent has also set up China's first Internet-connected hospital.
In January, Alibaba set up a connection between a small, remote fishing village and a hospital hundreds of miles away.
Villagers were able to teleconference with their doctors about their conditions, and doctors were able to diagnose and prescribe. For example, one fisherman filled out an online health form and spoke with the doctor online. That doctor wrote him a prescription and it, you guessed it, Alibaba's service and supply chain delivered the medicine to the fisherman's house the next day.
Healthcare spending in China is expected to rise from about $350 billion last year to a $1 trillion by 2020, according to research firm McKinsey & Co.
Source: Money Morning
http://moneymorning.com/2016/04/05/chin ... e-by-2020/
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Re: Healthcare 02 (May 15 - Dec 16)
by winston » Wed Apr 06, 2016 7:39 am
not vested
3 Medical Devices Stocks That Will Rule in 2016 and Beyond
After a choppy year, these companies are primed for a major rebound
By Josh Enomoto
Source; Investor Place
http://investorplace.com/2016/04/medica ... wRMDKR96M8
3 Medical Devices Stocks That Will Rule in 2016 and Beyond
After a choppy year, these companies are primed for a major rebound
By Josh Enomoto
Source; Investor Place
http://investorplace.com/2016/04/medica ... wRMDKR96M8
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 112857
- Joined: Wed May 07, 2008 9:28 am
Return to Business Sectors & Industries
Who is online
Users browsing this forum: No registered users and 4 guests